Dr. Kevin Horgan is a physician scientist in Philadelphia, PA. Born in London, his parents were natives of Clare and Cork. After attending Crescent College Comprehensive in Limerick he graduated in medicine from University College Cork in 1982. He completed postgraduate medical training at the Johns Hopkins Hospital in Baltimore, the National Cancer Institute in Bethesda, and UCLA in internal medicine, immunology and gastroenterology. After four years on the faculty at UCLA, where he specialized in managing inflammatory bowel disease, he joined the pharmaceutical industry at Merck Research Laboratories. There he led the development of the groundbreaking drug Emend for the prevention of nausea and vomiting associated with cancer chemotherapy. A decade after its approval in 2003, no similar drug has been successfully developed.
Since then, Kevin has developed several novel therapies and pharmaceuticals for inflammatory bowel disease and Alzheimer’s and his immunology research provided important early support for the development of three approved medications for multiple sclerosis, psoriasis, Crohn’s disease, and ulcerative colitis. Most recently he has been chief medical officer of Soligenix and Coronado Biosciences: both companies developing novel immunotherapies. He is currently working with several start-up companies in the U.S. and Ireland that are translating the discoveries of scientists and physicians into new therapies and diagnostics with emphasis on the immunotherapy of cancer, the microbiome, and healthy ageing.